Antibody discovery company Affinity Biosciences Pty Ltd reported on Wednesday the discovery of potent antibody binding to the SARS-CoV-2 virus spike protein that blocks the activity to prevent the virus from gaining a solid position in healthy people exposed to its infection.
Based in Melbourne, the company discovered several candidate antibodies that could neutralize SARS-CoV-2, the virus that causes COVID-19. The antibodies block the virus's spike protein from binding to the human receptor. Additionally, The Doherty Institute has also confirmed that these antibodies can completely neutralize SARS-CoV-2 infection in a single figure microgram / ml concentration in five-day virus neutralization assays. The antibodies have a high affinity for the SARS-CoV-2 spike protein of about 20 picomolar.
The company will seek an expedited process that enables the rapid manufacture of its antibodies to Good Manufacturing Practice (GMP) standards for clinical trials. Identification of expedited development routes with regulatory agencies (TGA, FDA and EMA) discussions are underway with governments, NGOs and pharmaceutical companies to achieve accelerated development and commercial distribution.
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Oscotec receives ODD from FDA for Cevidoplenib
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
TELA Bio launches LIQUIFIX for US hernia surgery
BD boosts US syringe production amid healthcare demand
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT
Upgraded Syngene International biologics facility to start operation in 2024
BioXcel Therapeutics secures European patent for method to treat agitation in dementia